Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Kleiman

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Cardiovascular Revascularization Medicine : Including Molecular Interventions|November 24, 2019
In-Hospital Outcomes with Transfemoral Versus Transapical Access for Transcatheter Aortic Valve Replacement in Patients with Peripheral Arterial DiseaseAyman Elbadawi, Syed Yaseen Naqvi, Marwan Saad, et al.
JACC. Case Reports|December 11, 2025
Transcatheter Tricuspid Valve Replacement in a Heart Transplant RecipientChloe Kharsa, Isadora Sande Mathias, Hassaan Bin Arshad, et al.
JACC. Cardiovascular Interventions|August 22, 2009
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registryVictor Novack, Donald Cutlip, Neal Kleiman, et al.
JACC. Cardiovascular Interventions|October 12, 2019
The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized TrialDavid A Burke, Harun Kundi, Alexandra Almonacid, et al.
JACC. Case Reports|June 25, 2026
Redo Transcatheter Aortic Valve Replacement for Degenerated Valve With High-Risk Coronary AnatomyChloe Kharsa, Gal Sella, Mangesh Kritya, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 27, 2019
Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacementSahil Khera, Dhaval Kolte, Salil Deo, et al.
Circulation|February 21, 2002
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trialMichael Simons, Brian H Annex, Roger J Laham, et al.
Journal of the American College of Cardiology|June 21, 2005
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trialHitinder S Gurm, Ian J Sarembock, Dean J Kereiakes, et al.
Circulation|February 6, 2008
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction, Eric Bates, Christoph Bode, et al.
Journal of the American College of Cardiology|September 11, 2020
Natural History of Functional Tricuspid Regurgitation Quantified by Cardiovascular Magnetic ResonanceYang Zhan, Dany Debs, Mohammad A Khan, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Cardiovascular Revascularization Medicine : Including Molecular Interventions|November 24, 2019
In-Hospital Outcomes with Transfemoral Versus Transapical Access for Transcatheter Aortic Valve Replacement in Patients with Peripheral Arterial DiseaseAyman Elbadawi, Syed Yaseen Naqvi, Marwan Saad, et al.
JACC. Case Reports|December 11, 2025
Transcatheter Tricuspid Valve Replacement in a Heart Transplant RecipientChloe Kharsa, Isadora Sande Mathias, Hassaan Bin Arshad, et al.
JACC. Cardiovascular Interventions|August 22, 2009
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registryVictor Novack, Donald Cutlip, Neal Kleiman, et al.
JACC. Cardiovascular Interventions|October 12, 2019
The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized TrialDavid A Burke, Harun Kundi, Alexandra Almonacid, et al.
JACC. Case Reports|June 25, 2026
Redo Transcatheter Aortic Valve Replacement for Degenerated Valve With High-Risk Coronary AnatomyChloe Kharsa, Gal Sella, Mangesh Kritya, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 27, 2019
Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacementSahil Khera, Dhaval Kolte, Salil Deo, et al.
Circulation|February 21, 2002
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trialMichael Simons, Brian H Annex, Roger J Laham, et al.
Journal of the American College of Cardiology|June 21, 2005
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trialHitinder S Gurm, Ian J Sarembock, Dean J Kereiakes, et al.
Circulation|February 6, 2008
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction, Eric Bates, Christoph Bode, et al.
Journal of the American College of Cardiology|September 11, 2020
Natural History of Functional Tricuspid Regurgitation Quantified by Cardiovascular Magnetic ResonanceYang Zhan, Dany Debs, Mohammad A Khan, et al.
Pageof 6